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Abstract
OBJECTIVE: To explore the role of Traditional Chi-
nese Medicine (TCM) in the prevention and treat-
ment of colorectal cancer and identify possible
therapeutic targets of TCM to provide clues for the
use of TCM for colorectal cancer prevention and
treatment in the clinic and to find novel directions
for new drug discovery for colorectal cancer.
METHODS:We used PubMed and Google to search
for and collect scientific publications for a full evalu-
ation of current evidence in the literature indicat-
ing the potential role of Chinese herbal medicines
and their respective ingredients as effective candi-
dates forcolorectalcancerpreventionandtreatment.
RESULTS: We extracted a detailed description of
potential therapeutic Chinese herbal medicines
and their constituent ingredients that target differ-
ent mechanisms in colorectal cancer such as gene
mutation, dysregulation of signaling pathways, me-
tabolism disorders, and the inflammatory microen-
vironment, including both conventional and
non-conventional approaches.
CONCLUSION: TCM may be a promising comple-
mentary and alternative therapy for the treatment
of colorectal cancer.
© 2016 JTCM. All rights reserved.
Key words: Colorectal neoplasms; Medicine, Chi-
nese traditional; Prevention and control; Therapeu-
tics; Drug delivery systems
INTRODUCTION
Colorectal cancer is a serious and fatal disease. Al-
though the specific pathogenetic mechanism is not ful-
ly proven, it is generally accepted that the risk factors
for colorectal cancer include a genetic component,
such as gene mutations, and an environmental compo-
nent, such as a high-fat diet.1 Current clinical treat-
ment of colorectal cancer mainly focuses on the use of
radiation therapy and chemotherapy. However, as
long-term use of these therapies causes serious side ef-
fects there is a need to find alternative therapies with
high efficacy but few side effects. Use of Traditional
Chinese Medicine (TCM) is an attractive approach for
the prevention and treatment of colorectal cancer
worldwide.2
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This paper focuses on the pathogenesis of colorectal
cancer and the efficacy of Chinese medicine in prevent-
ing and treating cancer with the aim of identifying pos-
sible therapeutic targets of Chinese herbal medicine
that might be beneficial in the prevention and treat-
ment of colorectal cancer.
METHODS
We searched PubMed and Google online up to July
2014 to find papers focusing on colorectal cancer pre-
vention and treatment to evaluate current evidence in
the literature indicating the potential role of Chinese
herbal medicines and their respective ingredients as ef-
fective candidates for colorectal cancer prevention and
treatment. The search terms used were: "Traditional
Chinese Medicine" or "Chinese Herbal Medicine" and
"Colon Cancer". Reference lists of the retrieved articles
were also reviewed for additional relevant studies.
RESULTS
Targeting kras and apc mutation in colorectal cancer
with TCM
Sporadic colorectal cancer in humans is caused by
long-term accumulation of multiple somatic mutations
in various genes, including oncogenes, tumor suppres-
sor genes, and epigenetic genes. The three routes of
cancer associated with genomic instability are chromo-
somal genomic instability (CIN), microsatellite insta-
bility, and a CpG island methylation phenotype
(CIMP). CIN is one of the main causative factors of
colon cancer (present in 80%-85% of cases), and is
closely related to the malignant progression of colorec-
tal cancer.3 CIN combined with mutation or inactiva-
tion of the adenomatous polyposis coli (APC) gene
and functional mutations in the β-catenin gene (CTN-
NB1) can lead to the formation of early intestinal ade-
nocarcinoma. Somatic APC mutation is present in ap-
proximately 90% of sporadic colorectal cancer tumor
tissues and can lead to constitutive β-catenin activation
and the subsequent activation of many genes involved
in the induction of tumorigenesis, such as c-myc.
Kras mutations in colorectal cancer patients are linked
to the patient's life span, tumor progression, and che-
motherapy resistance.4 In addition, Kras mutation com-
bined with APC loss synergistically increases Wnt sig-
naling, thus contributing to tumor growth and inva-
sion.5 The presence of a Kras mutation in a patient
with colorectal cancer therefore makes the disease hard-
er to treat.
Numerous studies have shown that Chinese herbal
medicine has a definite effect on colorectal cancer
through the regulation of gene expression. Resveratrol,
a major ingredient of Huzhanggen (Radix Polygoni Cus-
pidati), can induce colorectal cancer cell apoptosis,6 in-
hibit cell proliferation,7,8 and inhibit APCmin intestinal
tumor formation in mice.9 These chemopreventive
roles of resveratrol and other active ingredients in herb-
al medicines can be partially reflected by post-transcrip-
tional regulation and epigenetic modifications.10,11 For
example, resveratrol has been shown to increase the ex-
pression of miRNA-622 in colorectal cancer cells while
inhibiting the expression of Kras.12
Berberine, a main ingredient in Huanglian (Rhizoma
Coptidis), downregulates c-myc expression and increas-
es APC gene expression, thus interfering withβ-catenin nuclear translocation; in addition, berberine
intervention in APCMin/+ mice leads to smaller intestinal
tumor size and a decreased number of tumors through
inhibition of the Wnt / β-catenin signal.13
Colorectal cancer gene mutations are mainly concen-
trated in APC, Kras, and certain other genes, and such
mutations are considered the ultimate targets for block-
ing tumor angiogenesis and tumor cell proliferation
through the Wnt / β-catenin signal pathway. If TCM
or its single constituents could regulate downstream tar-
gets of β-catenin, it might be a perfect candidate for in-
hibition of the progression of colorectal cancer.
Targeting metabolism disorders in colorectal cancer
with TCM
Colorectal cancer is known to be associated with a
high-fat diet and colorectal metabolism disorders. Epi-
demiologic studies found that the incidence of colorec-
tal cancer and mortality rates vary geographically.14-16
There is evidence that diet and nutritional factors play
key roles in the onset and progression of colorectal can-
cer;17-20 consumption of a high-fat diet and genetic risk
factors can induce an energy imbalance and increase
the incidence of colorectal cancer.21-25 In ApcMin/+ mice, a
spontaneous increase in the number of intestinal tu-
mors is associated with a high-fat diet.26
AMP-activated protein kinase (AMPK) is one of the
key sensors for regulation of energy metabolism and is
also a key factor in the regulation of cell growth and
apoptosis.27-29 Once activated, AMPK can phosphory-
late many metabolic enzymes, inhibit the signaling
pathways of ATP consumption, and increase fatty acid
oxidation.30,31
Many flavonoids extracted from Chinese herbal medi-
cines, such as wogonin,32 tanshinoneⅡA,33 quercetin,34,35
and cryptotanshinone,36 can induce AMPK activation,
which then inhibits proliferation and induces apoptosis
of cancer cells.37 Therefore, selected pharmaceutical in-
gredients from TCM that target the activation of
AMPK may be helpful for colorectal cancer prevention
and treatment. There are more than 20 types of Chi-
nese herbal medicine that can be used for metabolic
disorders, and their main mechanisms of action are reg-
ulation of mitochondrial function and glucose metabo-
lism and stimulation of AMPK activation.38-40 Berber-
ine, an alkaloid from TCM, can significantly inhibit
colorectal cancer proliferation and tumor formation
through activation of AMPK.41
244
JTCM |www. journaltcm. com April 15, 2016 |Volume 36 | Issue 21 |
LiWD et al. / Review
Targeting key signaling pathways related to
colorectal cancer with TCM
Signaling pathways that are closely associated with the
incidence of colorectal cancer include Signal Transduc-
er and Activator of Transcription-3 (Stat3), Wnt, Mito-
gen-activated protein kinases (MAPK), and p53 path-
ways (Table 1); targeting the regulation of these path-
ways is an important approach to find effective antican-
cer candidates in TCM.
Stat3 signal pathway and colorectal cancer
Activation of Signal Transducer and Activator of Tran-
scription-3 (Stat3) is prevalent in tumor cells and in-
duces the expression a large number of genes involved
in tumor formation. Stat3 is an important target for
the prevention and treatment for colorectal cancer.52
Stat3 activation is negatively correlated with clinical an-
titumor results.53 Sustained Stat3 activation can affect
multiple levels of malignant change,54 including the in-
duction of cell cycle regulators, uncontrolled prolifera-
tion of cancer cells induced by cyclin D1 and c-myc,
and the induction of different antiapoptotic proteins
such as Bcl-2, Mcl-1, and Survivin for escape from
apoptosis. Stat3 activation also regulates proteins in-
volved in cancer invasion, metastasis, and angiogene-
sis.55 The role of Stat3 in the regulation of many genes
during carcinogenesis makes it a promising target for
cancer treatment.56
Many TCMs and their single components with
heat-clearing and detoxifying roles can significantly in-
hibit proliferation and induce apoptosis of colon can-
cer cells through regulation of the Stat3 signaling path-
way. Banzhilian (Herba Scutellariae Barbatae) can sup-
press the activation of Stat3 in colorectal cancer and
subsequently inhibit its downstream targets that are
linked to colon cancer cell proliferation and apopto-
sis.57 Quinazoline alkaloid, extracted from bitter beans,
can inhibit colon cancer cell proliferation and apopto-
sis through inhibition of Jak / Stat3 and PI-3K / AKT
signaling pathways.58 Xiakucao (Spica Prunellae Vulgar-
is) inhibits the proliferation of colorectal cancer cells,
induces apoptosis, and inhibits angiogenesis in colorec-
tal cancer tissue by inhibiting the phosphorylation of
Stat3.59 Experiments in tumor-bearing animals show
that Pientzehuang reduces tumor mass, accompanied
by inhibition of the phosphorylation of Stat3 in tumor
tissue.60
Wnt signal pathway and colorectal cancer
The Wnt pathway plays a leading role in the initiation
and progression of colorectal cancer.61 Although there
is a clear correlation between Wnt signaling and
colorectal cancer, drugs targeting this pathways are lim-
ited62 and it is necessary to find candidates targeting
downstream proteins of the Wnt signaling pathway, es-
pecially APC, AXIN2 (Axis inhibition protein 2), orβ-catenin. Therefore, it is important to search TCM
for candidates that can target the Wnt signaling path-
way for the prevention and treatment of colorectal cancer.
Tetrandra, extracted from Fangji (Radix Stephaniae Tet-
randrae), can inhibit the growth of colorectal tumors
and suppress cell proliferation through inhibition of
Botanical or chemical name
Huanglian (Rhizoma Coptidis)13,41
Yujin (Radix CurcumaeWenyujin)42
Baihuasheshecao (Herba Hedyotdis)43,44
Huanglian (Rhizoma Coptidis)13,41
Jianghuang (Rhizoma Curcumae Longae)45
Banmao (Mylabris Plalerata)46
Banzhilian (Herba Scutellariae Barbatae)47
Huangqi (Radix Astragali Mongolici)48
Houpu (Cortex Magnoliae Officinalis)49
Renshen (Radix Ginseng)50
Fangji (Radix Stephaniae Tetrandrae)51
Targeted signal pathway
Wnt/β-catenin
AMPK Inhibits colon tumor formation andinduces apoptosis In vitro and in vivo
MAPK
sonic hedgehog, Stat3,
Akt and p70S6K
Wnt/β-catenin
NF-κB/PI-3K/Src path-
ways
p38 MAPK and Akt
Akt and p53 pathways
mTOR signaling
and Erk signaling
Notch signaling
Wnt/β-catenin
Wnt/β-catenin
Activity
Inhibits colon tumor formation
Inhibits proliferation and induces
apoptosis
Inhibition of tumor angiogenesis
Inhibits colon tumor formation
Inhibition of IκBα kinase activation
and IκBα phosphorylation
Inhibitor of tumor angiogenesis
Inhibits proliferation and induces G1/
S arrest
Suppresses angiogenesis
Inhibits colon cancer growth
Blocks the nuclear translocation ofβ-catenin
Inhibits proliferation, viability, and xe-
nograft tumor growth
In vitro or in vivo
In vivo
In vitro
In vitro and in vivo
In vivo
In vitro
In vitro and in vivo
In vitro
In vitro and in vivo
In vitro and in vivo
In vitro
In vitro and in vivo
Notes: MAPK: mitogen-activated protein kinases; Stat3: signal transducer and activator of transcription-3; AKT: protein kinase B;
p70S6K: ribosomal protein S6 kinase; mTOR: mammalian target of rapamycin; NF-κB: nuclear factor kappaB; AMPK: Adenosine 5′-mo-
nophosphate (AMP)-activated protein kinase; PI-3K: phosphatidylinositol 3-kinase; Src: sarcoma gene; Erk: extracellular regulated protein
kinases.
Table 1 Targeting of signaling pathways in colorectal cancer by TCM
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β-catenin.51 Resveratrol has been found to inhibit the
proliferation of colon cancer cells and induce apoptosis
in vitro and in vivo in association with inhibition ofβ-catenin.63 Saud et al 64 found that isorhamnetin, a
chemical component of Puhuang (Pollen Typhae), pre-
vents colorectal tumor formation in mice by inhibiting
c-Src activation and the subsequent transcriptional acti-
vation of β-catenin.
MAPK signal pathway and colorectal cancer
Mammals possess three parallel MAPK signaling path-
ways: ERK1/2, JNK, and p38MAPK pathways. Of
these, the ERK1/2 signaling pathway is the key path-
way contributing to the survival and proliferation of tu-
mors, therefore targeting the ERK1/2 signaling path-
way by TCM is critical for colorectal cancer prevention
and treatment.
Evodiamine, an active ingredient of Wuzhuyu (Fructus
Evodiae Rutaecarpae), induces colorectal cancer cell
apoptosis by activating the JNK signaling pathway.65
Triptolide, a main ingredient of Tripterygium, inhibits
colon cancer cell viability and the cell cycle through
phosphorylation of ERK1/2 and AKT.66 Quercetin, a
major ingredient of Apocynum leaf extract, can regu-
late multiple signaling pathways including MEK/ERK
and Nrf/Keap1 signaling pathways.67 An active ingredi-
ent in magnolia extract, honokiol, enhances cell sensi-
tivity to oxaliplatin treatment while increasing the rate
of apoptosis and inhibiting growth of cancer cells
through phosphorylation of ERK1/2 and AKT.68
Based on abnormal signaling pathways, identification
of related upstream and downstream target genes
through genetic screening in patients and selection of
effective ingredients from TCM that block the mutant
target genes and proteins is a good approach to colorec-
tal cancer treatment.
Targeting the inflammatory microenviroment of
colorectal cancer with TCM
Inflammatory bowel diseases (IBD), including ulcer-
ative colitis and Crohn's disease, are linked to the inci-
dence of colorectal cancer.69 Therefore, treatment of in-
flammatory bowel disease is an important approach in
the prevention and treatment of colorectal cancer. Re-
cent results show that many herbal medicines have du-
al roles as anti-inflammatory and antitumor agents (Ta-
ble 2).
Baicalein, the main ingredient of Huangqin, can inhib-
it colorectal cancer in vivo and in vitro by inhibiting
NF-κB activation to reduce the number of intestinal
tumors.71 Salvia extract can significantly alleviate the
symptoms of intestinal inflammation and serves as a
better candidate for colitis-associated carcinogenesis.72
The extract of Houttuynia inhibits colorectal cancer
cell growth and induces apoptosis through inhibition
of mitochondrial enzymes.78 TCMs that are currently
in use as anti-inflammatory agents should not be limit-
ed to one kind of disease; their anti-inflammatory prop-
erties may also be beneficial for colitis-associated carci-
nogenesis.
DISCUSSION
Based on the above analysis, we found that both Chi-
nese medicines and their constituent compounds with
multiple targets were promising candidates for colorec-
tal cancer prevention and treatment. The development
of colorectal cancer is a chronic multi-step process, and
TCMs with different characteristics could be used to
target different stages of colorectal cancer progression.
Herbals with anti-inflammatory properties can be used
at earlier stages of colorectal cancer progression for ear-
ly prevention to reduce inflammatory symptoms, and
even tumor formation, of colorectal cancer. Moreover,
TCM may be combined with chemical drugs to allevi-
ate the inflammatory intestinal microenvironment to
delay the tumor burden. These notions suggest that we
should be focused on clinical early intervention and
Table 2 Chinese herbals and their extracts that target the inflammatory microenvironment of colorectal cancer in vivo
Family and botanical name
Huanglian (Rhizoma Coptidis)41
Huangqin
(Radix Scutellariae Baicalensis)70,71
Danshen (Radix Salviae Miltiorrhizae)72
Juhua (Flos Chrysanthemi)73
Yiyiren (Semen Coicis)74
Huangqi (Radix Astragali Mongolici)75
Juemingzi (Semen Cassiae Obtusifoliae)76
Roucongrong
(Herba Cistanches Deserticolae)77
Part used
Root Berberine AOM/DSS-induced colorectal carcinogenesis Mouse
Root
Root
Root
Flower
Fruit
Root
Fruit
Stem
Extract
Wogonin
Baicalein
Salvia
Digitoflavone
Adlay
Astragalus Saponins
H2O Extract
H2O Extract
Model
AOM/DSS-
induced colorectal carcinogenesis
AOM/DSS-
induced colorectal carcinogenesis
AOM/DSS-
induced colorectal carcinogenesis
AOM/DSS-
induced colorectal carcinogenesis
AOM/DSS-
induced colorectal carcinogenesis
Colorectal xenograft
Colorectal xenograft
Helicobacter infection
Mammal tested
Mouse
Mouse
Mouse
Mouse
Rat
Mouse
Mouse
Mouse
Notes: AOM: azoxymethane; DSS: dextran sulfate sodium.
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prevention, especially for patients who have inflamma-
tory bowel disease. Using TCM with anti-inflammato-
ry properties at an earlier time may be beneficial for
both reducing the inflammatory bowel disease and
blocking further progression of the colorectal cancer, as
reflected in the concepts emphasized by TCM of "pre-
vention before disease and anti-transformation after dis-
ease."
In addition, we found that both TCM and its single
constituents have multiple targets, which is totally dif-
ferent from chemical therapies with only a single tar-
get. This suggests that we can detect genes involved in
intestinal metabolism by screening different cancer pa-
tients, and then select specific gene-targeted herbal
medicines for their treatment. For example, herbal
medicines that promote blood circulation may have a
stronger effect on the Stat3 signaling pathway for
colorectal cancer treatment, whereas Chinese herbals
with heat clearing and dampness drying characters may
have a stronger effect on the Wnt signaling pathway or
the inflammatory NF-кB signaling pathway for
colorectal cancer treatment. Chinese herbal medicines
with multiple targets may be the best choice for
colorectal cancer prevention and treatment.
We can select Chinese herbal medicines that regulate
tumor metabolism for clinical intervention in accor-
dance with their specific characteristics. For example,
Chinese medicine monomers and compounds that can
activate AMPK have some similarities and can all be
used for the treatment of diabetes and other metabolic
disorders; this suggests that we may find new drugs
and effective ingredients for colorectal cancer preven-
tion and treatment among this kind of Chinese herbal
medicine.
The inflammatory microenvironment plays a key role
in multiple processes during the progression of colon
cancer. This provides us with the opportunity to find
effective therapeutic compounds from herbal medi-
cines with anti-inflammatory characteristics. We
should explore effective compounds from TCM for
colorectal cancer treatment based on our knowledge of
the characteristics, taste, and meridians of these Chi-
nese herbal medicines. We should also consider the ris-
ing, falling, floating, sinking and other features of the
herbal medicine for colorectal cancer prevention and
treatment, rather than depending only on its anti-in-
flammatory properties.
The development and progression of colorectal cancer
is a complex process involving multiple links and mech-
anisms that cannot be targeted by a single medicinal
drug against a single target. Rather, we should consider
integration of the different characteristics of Chinese
medicines to compose one prescription with multiple
targets for the prevention and treatment of colorectal
cancer. Finding effective candidates for colorectal can-
cer treatment among TCMs should be based on combi-
nation of the concepts of "treatment based on the over-
all" and "treatment based on syndrome differentia-
tion", and the consideration of "local symptoms" and
"global symptoms" of the patients. Moreover, we
should aim to use TCM to maximize clinical efficiency
while minimizing toxicities for optimal prevention and
treatment of colorectal cancer.
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